After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) congress, as they ...

asthma and chronic obstructive pulmonary disease (COPD). Sanofi reported in its Q4 2024 results that Dupixent surpassed its €13bn ($13.6bn) sales target for the full year, reaching $14.15bn sales.

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

This health education program aims to help patients living with COPD experience better health outcomes and improved quality ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

Sanofi’s SNY stock has declined 10.2% in ... prurigo nodularis and chronic obstructive pulmonary disease (COPD). Dupixent is now annualizing at close to €11.0 billion in sales after almost ...

General Manager at Sanofi UK and Ireland, Rippon Ubhi, and Jim Shannon MP discuss the burden of chronic obstructive pulmonary ...

As the UK endures another harsh winter, plummeting temperatures and a surge in respiratory infections are placing strain on ...

COPD is an inflammatory lung disease ... NAH received honoraria for serving as an advisor/consultant for GSK, Sanofi, Genentech, Verona Pharma, Astra Zeneca, and Boehringer Ingelheim, and research ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ... chronic spontaneous urticaria (CSU), and chronic obstructive pulmonary disease (COPD) in different age populations.